A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Aug 31, 2012

Pasetocin® and Sawacillin® : Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitors and either Clarithromycin or Metronidazole

Read more about Pasetocin® and Sawacillin® : Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitors and either Clarithromycin or Metronidazole
Aug 30, 2012

U.S. FDA Approves XTANDI® (enzalutamide) After Priority Review for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated with Docetaxel

- Medivation to host conference call today at 11:45am PT -

Read more about U.S. FDA Approves XTANDI® (enzalutamide) After Priority Review for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated with Docetaxel
Aug 15, 2012

New England Journal of Medicine Publishes Results from Phase 3 AFFIRM Trial of Enzalutamide

Read more about New England Journal of Medicine Publishes Results from Phase 3 AFFIRM Trial of Enzalutamide
Aug 10, 2012

Astellas and AstraZeneca announce the approval in Japan of the dry-power inhaler Symbicort® Turbuhaler® for the additional indication of chronic obstructive pulmonary disease (COPD)

Tokyo, Japan, August 10, 2012 – Astellas Pharma Inc. (“Astellas”, headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) and AstraZeneca K.K. (“AstraZeneca”, headquarters: Osaka;...

Read more about Astellas and AstraZeneca announce the approval in Japan of the dry-power inhaler Symbicort® Turbuhaler® for the additional indication of chronic obstructive pulmonary disease (COPD)
Aug 8, 2012

Astellas Pharma: Application for Orally Disintegrating Tablet YM060, a Treatment for Diarrhea-predominant Irritable Bowel Syndrome, in Japan

Tokyo, August 8, 2012 - Astellas Pharma Inc. (“Astellas Pharma”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) today announced that it submitted an application for market authorization...

Read more about Astellas Pharma: Application for Orally Disintegrating Tablet YM060, a Treatment for Diarrhea-predominant Irritable Bowel Syndrome, in Japan

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts